GenoMed, Inc. Completes Agreement To Manage Southwestern US Distribution Of Its Clinical Outcomes Improvement Program(TM)
ST. LOUIS, Aug. 8 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has completed a contract with Parks Health Care, Inc of Phoenix, Arizona ("PHC") to introduce its Clinical Outcomes Improvement Program(TM) to physician organizations in Arizona, New Mexico and Nevada.
Parks Health Care is a leading consultant to physicians specializing in group purchasing and physician education.
Sue Parks, President and CEO of Parks Health Care, stated that, "It is appropriate that Phoenix has been designated as one of the centers for GenoMed's medical genomics effort. The Phoenix area is a mecca for healthy baby-boomers and retirees. There is huge interest among our Physicians in becoming GenoMed-certified. It allows our physicians to bring the benefits of the Genomic Revolution to their patients and help supplement their income as well. The GenoMed program delivers a great value."
Under the agreement, PHC will introduce and support the program of GenoMed's Clinical Outcomes Improvement Program(TM) to more than 2,500 physicians across the Southwestern United States.
GenoMed is currently negotiating agreements with large physician organizations in markets across the United States. GenoMed is also in conversations with international markets as well.
Dr. David Moskowitz, GenoMed's Chairman, said, "We are delighted to have Parks Health Care actively involved in our program. They are a great partner in a great market. The Phoenix/Sun Valley population of retirees and baby- boomers are a perfect fit for our Clinical Outcomes Improvement Program(TM). We anticipate that our novel program will allow a better quality of life and greatly reduce overall health care costs that are the usual burden of aging."
Dr. Moskowitz added, "We continue to be excited about the growing number of physician organizations that are embracing GenoMed's mission of preventive molecular medicine, and who are interested in becoming part of our Clinical Outcomes Improvement Network(TM). We hope in the coming years to capture a significant portion of practicing physicians in the United States."
The Clinical Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients' health dramatically while positively differentiating a physician's practice in the medical marketplace.
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com .
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., 1-877-436-6633, or fax,
+1-314-977-0042, email: kfischer@genomedics.com
Web site: genomedics.com
. |
